C M Bidwell & Associates Ltd. Has $4.12 Million Position in IDEXX Laboratories, Inc. (IDXX)

C M Bidwell & Associates Ltd. trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 19.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,535 shares of the company’s stock after selling 6,155 shares during the period. C M Bidwell & Associates Ltd.’s holdings in IDEXX Laboratories were worth $4,122,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. D.A. Davidson & CO. grew its holdings in IDEXX Laboratories by 160.4% during the 2nd quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock valued at $100,000 after purchasing an additional 385 shares during the last quarter. Sun Life Financial INC grew its holdings in IDEXX Laboratories by 9,085.7% during the 2nd quarter. Sun Life Financial INC now owns 643 shares of the company’s stock valued at $104,000 after purchasing an additional 636 shares during the last quarter. Capital Advisors Ltd. LLC bought a new position in IDEXX Laboratories during the 2nd quarter valued at about $128,000. Global X Management Co. LLC grew its holdings in IDEXX Laboratories by 44.6% during the 1st quarter. Global X Management Co. LLC now owns 1,047 shares of the company’s stock valued at $162,000 after purchasing an additional 323 shares during the last quarter. Finally, Flagship Harbor Advisors LLC bought a new position in IDEXX Laboratories during the 1st quarter valued at about $200,000. Institutional investors own 87.64% of the company’s stock.

Several brokerages recently commented on IDXX. Canaccord Genuity reiterated a “buy” rating and set a $180.00 price target on shares of IDEXX Laboratories in a report on Friday. Bank of America Corporation upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a report on Wednesday, August 23rd. Stifel Nicolaus reiterated a “buy” rating and set a $185.00 price target on shares of IDEXX Laboratories in a report on Monday, August 21st. BidaskClub downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, CL King upgraded shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price target on the stock in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $174.00.

WARNING: “C M Bidwell & Associates Ltd. Has $4.12 Million Position in IDEXX Laboratories, Inc. (IDXX)” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://transcriptdaily.com/2017/10/08/c-m-bidwell-associates-ltd-has-4-12-million-position-in-idexx-laboratories-inc-idxx.html.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) traded up 0.54% during trading on Friday, reaching $158.97. 544,504 shares of the company’s stock were exchanged. The company has a 50 day moving average of $155.81 and a 200 day moving average of $159.71. The stock has a market cap of $13.87 billion, a P/E ratio of 54.69 and a beta of 0.48. IDEXX Laboratories, Inc. has a 12-month low of $102.45 and a 12-month high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.95 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. IDEXX Laboratories had a net margin of 14.13% and a negative return on equity of 473.46%. The business had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. During the same period last year, the business earned $0.74 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

In other IDEXX Laboratories news, Chairman Jonathan W. Ayers sold 58,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $155.00, for a total transaction of $8,990,000.00. Following the completion of the sale, the chairman now directly owns 1,043,034 shares in the company, valued at $161,670,270. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Jonathan W. Ayers sold 17,000 shares of IDEXX Laboratories stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $154.54, for a total transaction of $2,627,180.00. Following the sale, the chairman now owns 1,039,034 shares of the company’s stock, valued at $160,572,314.36. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 151,734 shares of company stock valued at $23,436,626. Company insiders own 2.77% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply